NCT06540937View on ClinicalTrials.gov

Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Neuroendocrine Tumors
Interventions
DRUG

Leflunomide Pill

This is a single-arm, single-center, phase II clinical study. Primarily evaluated in advanced MEN-1 neuroendocrine tumors. The initial efficacy of leflunomide tablets in second-line treatment provided evidence for phase III clinical trials.

Trial Locations (1)

100021

RECRUITING

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER